

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/272033 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/765 (2006.01)
C07K 14/725 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/034856

(22) International Filing Date:

24 June 2022 (24.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/214,963 25 June 2021 (25.06.2021) US
63/276,804 08 November 2021 (08.11.2021) US
63/328,603 07 April 2022 (07.04.2022) US

(71) Applicant: **HARPOON THERAPEUTICS, INC.**

[US/US]; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: **WESCHE, Holger**; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

LIN, Shuoyen Jack; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

KWANT, Kathryn; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

(US). **LEMON, Bryan D.**; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

AUSTIN, Richard J.; 131 Oyster Point Boulevard, Suite 300, South San Francisco, California 94080 (US).

(74) Agent: **WANG, Yingjiao**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: EXTENDED-RELEASE IMMUNE CELL ENGAGING PROTEINS AND METHODS OF TREATMENT

(57) Abstract: Provided herein is descriptions of extended-release immune cell binding protein comprising a masking peptide and cleavable linker, and the methods of using thereof. Also described is a pharmaceutical composition comprising a protein with a masking peptide and a cleavable linker, and the method of using thereof.

TriTAC XR

Intact




FIG. 1A

WO 2022/272033 A3

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

16 February 2023 (16.02.2023)